SCHEMBL6941465

SCHEMBL6941465

O=C(NCc1ccccc1)c1cc([N+](=O)[O-])ccc1NC(CO)CO

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 6/20 0.57
KMT2A Q03164 6/20 0.57
MAPT P10636 6/20 0.57
GAA P10253 2/20 0.57
ALDH1A1 P00352 3/20 0.51
SMN1; SMN2 Q16637 1/20 0.49
CYP1A2 P05177 3/20 0.49
CYP3A4 P08684 2/20 0.49
CYP2C19 P33261 2/20 0.49
HPGD P15428 1/20 0.49
AKR1C3 P42330 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
CYP2C9 P11712 2/20 0.47
PKM P14618 1/20 0.47
NPC1 O15118 1/20 0.47
TRPA1 O75762 1/20 0.47
LMNA P02545 1/20 0.47
TSHR P16473 1/20 0.47
CDK2 P24941 1/20 0.47
MAPK1 P28482 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6939652 0.88 MEN1 (0.52) MEN1KMT2AMAPTGAAALDH1A1
SCHEMBL7073458 0.83 MAPT (0.48) MEN1KMT2AMAPTGAAALDH1A1
SCHEMBL7073454 0.83 MAPT (0.48) MEN1KMT2AMAPTGAAALDH1A1
SCHEMBL6939880 0.82 MEN1 (0.45) MEN1KMT2AMAPTGAAALDH1A1
SCHEMBL7566052 0.82 GABRP (0.52) MEN1KMT2AMAPTALDH1A1SMN1; SMN2
SCHEMBL6941788 0.81 ALDH1A1 (0.63) MEN1KMT2AMAPTGAAALDH1A1
SCHEMBL6943727 0.81 RORC (0.48) MEN1KMT2AMAPTALDH1A1SMN1; SMN2
SCHEMBL6941371 0.81 FFAR1 (0.51) MEN1KMT2AMAPTGAAALDH1A1
SCHEMBL6941364 0.81 FFAR1 (0.51) MEN1KMT2AMAPTGAAALDH1A1
SCHEMBL6940854 0.81 ALDH1A1 (0.44) MAPTALDH1A1SMN1; SMN2HPGDLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1080069-B1 ANTHRANILIC ACID DERIVATIVES AS INHIBITORS OF THE CGMP-PHOSPHODIESTERASE FUJISAWA PHARMACEUTICAL CO (JP) 2003-03-19 EP claimed
US-20020193614-A1 Anthranilic acid derivatives as inhibitors of the CGMP-phosphodiesterase FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2002-12-19 US claimed
EP-1080069-B1 ANTHRANILIC ACID DERIVATIVES AS INHIBITORS OF THE CGMP-PHOSPHODIESTERASE FUJISAWA PHARMACEUTICAL CO (JP) 2003-03-19 EP disclosed
US-20020193614-A1 Anthranilic acid derivatives as inhibitors of the CGMP-phosphodiesterase FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2002-12-19 US disclosed
US-6384080-B1 TREATMENT AND/OR PREVENTION OF CERTAIN CARDIOVASCULAR DISORDERS, UROGENITAL DISORDERS, RESPIRATORY SYSTEM DISORDERS, DISORDERS OF GUT MOTILITY, SEXUAL DISORDERS, DIABETIC COMPLICATIONS, URTICARIA FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-05-07 US disclosed
CN-1305454-A Anthranilic acid derivatives as inhibitors of CGMP phosphodiesterase FUJISAWA PHARMACEUTICAL CO (JP) 2001-07-25 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020193614-A1 Anthranilic acid derivatives as inhibitors of the CGMP-phosphodiesterase PDE3A, PDE2A, PDE5A MEN1 2660/4885KMT2A 1991/4885MAPT 4706/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.